These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36971800)

  • 41. Structural and clinical changes in previously treated type 1 macular neovascularization in non-responder AMD eyes switched to brolucizumab.
    Pece A; Fossataro F; Maione G; Liuzzi R
    Eur J Ophthalmol; 2024 Jan; 34(1):245-251. PubMed ID: 37150939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of Vascular Versus Avascular Subretinal Hyperreflective Material With Aflibercept Response in Age-related Macular Degeneration.
    Kawashima Y; Hata M; Oishi A; Ooto S; Yamashiro K; Tamura H; Miyata M; Uji A; Ueda-Arakawa N; Tsujikawa A
    Am J Ophthalmol; 2017 Sep; 181():61-70. PubMed ID: 28669776
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytokine profiles in the aqueous humor following brolucizumab administration for exudative age-related macular degeneration.
    Terao R; Obata R; Okubo A; Aoki S; Azuma K; Ahmed T; Inoda S; Hashimoto Y; Takahashi R; Yoshida H; Misawa M; Takahashi H; Takahashi H
    Graefes Arch Clin Exp Ophthalmol; 2023 Sep; 261(9):2465-2476. PubMed ID: 37000271
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center.
    Nguyen HV; Li AS; Silva AR; Leng T
    Eur J Ophthalmol; 2022 Sep; 32(5):2747-2751. PubMed ID: 34761684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data.
    Radke NV; Mohamed S; Brown RB; Ibrahim I; Chhablani J; Amin SV; Tsang CW; Brelen ME; Raichand NS; Fang D; Zhang S; Dai H; Chen GLJ; Cheung CMG; Hariprasad SM; Das T; Lam DSC
    Asia Pac J Ophthalmol (Phila); 2023 Mar-Apr 01; 12(2):168-183. PubMed ID: 36971706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry.
    MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
    Ophthalmology; 2023 Sep; 130(9):937-946. PubMed ID: 37086857
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment.
    Baumal CR; Bodaghi B; Singer M; Tanzer DJ; Seres A; Joshi MR; Feltgen N; Gale R
    Ophthalmol Retina; 2021 Jun; 5(6):519-527. PubMed ID: 33007521
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
    Inan S; Polat O; Karadas M; Inan UU
    Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
    [No Abstract]   [Full Text] [Related]  

  • 49. Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes - A multicentric study.
    Chakraborty D; Mondal S; Sengupta S; Abbas Z; Chandra K; Boral S; Maiti A; Roy S; Mukherjee A; Das A; Chakraborty S; Nag P
    Indian J Ophthalmol; 2023 May; 71(5):1979-1985. PubMed ID: 37203069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
    Prahs P; Brandl C; Helbig H; Volz C
    Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
    [No Abstract]   [Full Text] [Related]  

  • 51. Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study.
    Bilgic A; Kodjikian L; de Ribot FM; Spitzer MS; Vasavada V; Gonzalez-Cortes JH; Sudhalkar A; Chakraborty S; Mathis T
    Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1161-1167. PubMed ID: 38063874
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
    Shigemoto Y; Sakurada Y; Fukuda Y; Matsubara M; Parikh R; Kashiwagi K
    Medicine (Baltimore); 2021 Oct; 100(42):e27580. PubMed ID: 34678906
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation.
    Hikichi T
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2529-2535. PubMed ID: 35235038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brolucizumab for Wet Age-Related Macular Degeneration: One-Year Real-World Experience from a Tertiary Center.
    Scupola A; Carlà MM; Boselli F; Giannuzzi F; De Filippis A; Fossataro C; Minnella AM; D'Amico G; Coppola G; Savastano MC; Sammarco MG; Rizzo S
    Ophthalmologica; 2023; 246(1):58-67. PubMed ID: 36843038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration-up to 10 years of follow-up.
    Park JY; Park YJ; Park SJ; Park KH; Yeo JH; Kim JG; Yoon YH; Lee JY; Woo SJ
    Acta Ophthalmol; 2022 Dec; 100(8):e1579-e1588. PubMed ID: 35363434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Potential pitfalls of anti-VEGF therapy of neovascular age-related macular degeneration].
    Kovalevskaya MA; Pererva OA; Roldugin AA; Kartamyshev EG
    Vestn Oftalmol; 2021; 137(6):149-156. PubMed ID: 34965081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ADVANTAGES OF OPTICAL COHERENCE TOMOGRAPHY AS A HIGH DYNAMIC RANGE IMAGING MODALITY IN SUBRETINAL HYPERREFLECTIVE MATERIAL.
    Montolío-Marzo S; Gallego-Pinazo R; Palacios-Pozo E; Dolz-Marco R
    Retina; 2023 Apr; 43(4):641-648. PubMed ID: 36729623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
    Inoda S; Takahashi H; Maruyama-Inoue M; Ikeda S; Sekiryu T; Itagaki K; Matsumoto H; Mukai R; Nagai Y; Ohnaka M; Kusuhara S; Miki A; Okada AA; Nakayama M; Nishiguchi KM; Takeuchi J; Mori R; Tanaka K; Honda S; Kohno T; Koizumi H; Miyara Y; Inoue Y; Takana H; Iida T; Maruko I; Hayashi A; Ueda-Consolvo T; Yanagi Y
    Retina; 2024 Apr; 44(4):714-722. PubMed ID: 38016089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
    Freund KB; Staurenghi G; Jung JJ; Zweifel SA; Cozzi M; Hill L; Blotner S; Tsuboi M; Gune S
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2437-2447. PubMed ID: 35239009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.